Current Agents Approved for Treatment of HCC
Ghassan Abou-Alfa, MD, discusses the approved agents available for the treatment of hepatocellular carcinoma. Compared to 2007 when there was only 1 agent available, sorafenib, there is now a great number of options for these patients.
Ghassan Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the approved agents available for the treatment of hepatocellular carcinoma (HCC). Compared to 2007 when there was only 1 agent available, sorafenib (Nexavar), there is now a great number of options for these patients.
In the frontline setting, lenvatinib (Lenvima) is approved. In the second-line, regorafenib (Stivarga) is approved for use after patients have progressed on sorafenib. There is also a conditional approval for nivolumab (Opdivo) in the second-line setting of HCC.
Encouraging data is available for cabozantinib (Cabometyx) in the second- and third-line settings, as well as ramucirumab (Cyramza) in the second-line for patients with high alpha-fetoprotein.
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
